방사선의학 웹진

바로가기  >

Abstract

To evaluate the efficacy of 18F-FC119S as a positron emission tomography (PET) radiopharmaceutical for the imaging of Alzheimer's disease (AD), we studied the drug absorption characteristics and distribution of 18F-FC119S in normal mice. In addition, we evaluated the specificity of 18F-FC119S for β-amyloid (Aβ) in the AD group of an APP/PS1 mouse model and compared it with that in the wild-type (WT) group. The behavior of 18F-FC119S in the normal mice was characteristic of rapid brain uptake and washout patterns. In most organs, including the brain, 18F-FC119S reached its maximum concentration within 1 min and was excreted via the intestine. Brain PET imaging of 18F-FC119S showed highly specific binding of the molecule to Aβ in the cortex and hippocampus. The brain uptake and binding values for the AD group were higher than those for the WT group. These results indicated that 18F-FC119S would be a candidate PET imaging agent for targeting Aβ plaque.

Author information

Oh SJ1,2, Kim MH1, Han SJ1, Kang KJ1, Ko IO1, Kim Y3, Park JA1, Choi JY1, Lee KC1, Chi DY4, Lee YJ1, Kim KM2,5.

1Division of RI-Convergence Research, Korea Institute Radiological and Medical Sciences , 01812 Seoul, Korea.2Radiological & Medico-Oncological Sciences, Korea University of Science and Technology , 34113 Daejeon, Korea.3Department of Pharmacy and Integrated Science and Engineering Division, Yonsei University , 03722 Incheon, Korea.4Research Institute of Labeling, FutureChem Co., Ltd , Seoul 04782, Republic of Korea.5Division of Medical Radiation Equipment, Korea Institute Radiological and Medical Sciences , 01812 Seoul, Korea.